密歇根大学试验,利用干细胞改善对无严重副作用的高级干燥AMD病人的视力。 A University of Michigan trial using stem cells improved vision in advanced dry AMD patients with no serious side effects.

在密歇根大学进行的临床试验显示,利用成人干细胞移植治疗高级干燥年龄与肌肉畸形有关的畸形(AMD)的临床试验取得了早期成功,有6名病人的视力得到改善,没有产生严重的副作用。 A clinical trial at the University of Michigan using adult stem cell transplants to treat advanced dry age-related macular degeneration (AMD) has shown early success, with six patients experiencing improved vision and no serious side effects. 这种治疗涉及从捐献者眼组织中提取的视网膜色素上皮细胞,一年后,在眼图上平均增加21个字母,未受治疗的眼睛没有改善。 The treatment, involving retinal pigment epithelial cells from donor eye tissue, led to an average gain of 21 letters on an eye chart one year later, with no improvement in untreated eyes. 由国家卫生研究所资助的研究公布在细胞清点细胞中,该研究正在扩大,将增加12名接受更高剂量细胞的参与者。 The NIH-funded study, published in Cell Stem Cell, is expanding to include 12 more participants receiving higher cell doses. 研究者称这些结果对先进的AMD来说是有希望的和前所未有的,这是一个影响到大约2 000万美国人的状况,他们目前没有恢复视力的治疗方法。 Researchers call the results promising and unprecedented for advanced AMD, a condition affecting about 20 million Americans that currently has no vision-restoring treatment.